Arcturus Therapeutics (ARCT) catalysts

Upcoming FDA decisions and readouts we track for Arcturus Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 12 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Arcturus Therapeutics (ARCT, listed on Nasdaq). They cover 2 programmes: ARCT-810 (Ornithine transcarbamylase deficiency) and ARCT-032 (Cystic fibrosis (inhaled mRNA)).

First on the list: the Phase 2 readout for ARCT-810 (Ornithine transcarbamylase deficiency), guided by the company to Q3 2026. By stage, the upcoming rows are 2 Phase 2 readouts.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: ARCT
Next catalyst: Q3 2026
Type: Phase 2 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Arcturus Therapeutics ARCT · Nasdaq	ARCT-810	Ornithine transcarbamylase deficiency	Q3 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Data and the regulatory plan for this program is expected to be communicated later this quarter." Source: 8-K exhibit 99.1, filed 06 Aug 2026 · verified 12 Sep 2026
Arcturus Therapeutics ARCT · Nasdaq	ARCT-032	Cystic fibrosis (inhaled mRNA)	Q4 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "The decision to advance ARCT-032 into Phase 3 is expected in Q4 2026" — the decision follows the Phase 2 data. Source: 8-K exhibit 99.1, filed 06 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

4D Molecular Therapeutics (FDMT)Cystic fibrosis lung disease; Wet age-related macular degeneration
Insmed (INSM)Non-cystic fibrosis bronchiectasis (Japan)
Cartesian Therapeutics (RNAC)Myasthenia gravis (mRNA CAR-T); Myositis; Juvenile dermatomyositis (paediatric); Myasthenia gravis
Invivyd (IVVD)COVID-19 prevention (monoclonal antibody); COVID-19 safety versus mRNA vaccine

Also due in Q4 2026

Jasper Therapeutics (JSPR)Phase 2 readout for KP-104, Q4 2026
SELLAS Life Sciences Group (SLS)Phase 2 readout for SLS009 (tambiciclib), Q4 2026
Rapport Therapeutics (RAPP)Phase 2 readout for RAP-219, Oct 2026
PMV Pharmaceuticals (PMVP)Phase 2 readout for Rezatapopt, Q4 2026
Spyre Therapeutics (SYRE)Phase 2 readout for SPY072, Q4 2026
Structure Therapeutics (GPCR)Phase 2 readout for Aleniglipron, Q4 2026